Faculty Grants Our department has been granted over $10,907,029 in NIH funds!
“G-protein Signaling Reduces Neurodegeneration and Promotes Recovery of Synaptic Strength following Traumatic Brain Injury”
The amount of funding is $300,000 for the period 1/15/17 to 1/14/2020. This project investigates the role of RIT1 G-protein signaling in cellular and functional recovery from brain trauma.
(with Jon Satin)
“Monomeric G-proteins and Cardioprotection From Heart Failure”
The amount of funding (total direct plus indirect for 3 years) is approximately 1.6 million dollars. This project investigates the hypothesis that Rad modulates the interdependent relationship between LTCC and β-AR signaling and that Rad deficiency promotes protection against adverse myocardial remodeling.
St. Baldrick's Foundation for Pediatric Cancer Research:
"Protein Tyrosine Phosphatases as Novel Drugs Targets in Acute Lymphoblastic Leukemia"
$100,000. 6/1/17-5/30/18. This goal of this research is to use zebrafish screens and human leukemia cells to identify FDA-approved
tyrosine phosphatase inhibitors that can be repurposed as targeted anti-cancer therapy in pediatric leukemia.
"Development of Fusion Oncoprotein Models in Zebrafish"
$163,000. 8/1/17-11/30/18. In response to the Cancer Moonshot Initiative, and in collaboration with St. Jude Children's Research Hospital, this project will use CRISPR technology to develop the first zebrafish models of translocations common to pediatric cancers, with the goal of developing new high- throughput, in vivo drug screening tools.
NIH New Innovator Award:
"Harnessing Single-Cell Technology to Define Self-Renewal of Normal and Malignant Stem Cells"
$2.3 million, 9/1/17-8/30/22. This project utilizes zebrafish leukemia models for single-cell sequencing and high resolution in vivo imaging to define the unique biological properties of cancer stem cells, to understand how they respond to chemotherapy in vivo, and to identify new ways to target them therapeutically to prevent leukemia relapse.
COBRE Pilot Award:
“Interplay Between Calcineurin, Rcan1, and Tau in Alzheimer’s Disease”
$100,000, 5/1/2017-4/30/2018. In this project, we are investigating tau undergoing liquid-liquid phase separation, how that is affected by phosphorylation state and dephosphorylation by calcineurin and the role of Rcan1 in modulating these processes.
VPR Research Support Grant:
“Inhibition of Calcineurin by Rcan1 and Hyperphosphorylation of Tau in Alzheimer’s Disease”
$10,000, 7/1/2017-6/30/2017. The goal of this project is to determine the extent to which Rcan1 inhibits calcineurin’s dephosphorylation of tau and how that contributes to neurofibrillary tangle formation in Alzheimer’s disease.
“Characterization of the Sch9 Longevity Pathway in Yeast”
The amount of funding (direct plus indirect) is $382,500, and the grant runs from 09/01/2017 to 08/31/2018.
NIH S10 Award
Industry Sponsored Project: Valerion Therapeutics:
“Defining the Action of Fab-Amylase as a Putative Therapeutic for LD”
The amount of funding is $415,000 and the grant runs from 2017-2019.
Multi-PI COBRE Pilot Grant:
“Structural and Biochemical Perspective of Cell-Wall Biosynthesis in Gram-Positive Bacteria”
The amount of funding is $50,000 and the grant runs from 2017-2018. The main objective of the grant is to elucidate the mechanism of biogenesis of Group-specific polysaccharides in pathogenic Streptococci.
(With Natalia Korotkov and Jeffrey Rush)
PI on an R21
“Changing Serotonin Receptor 2C Splice Variants to Combat Spasticity After Spinal Cord”
The award is in the amount of $225,750.
Grant for Prader Willi Research
“Molecular Mechanism of Platelet Exocytosis”
The amount of funding is $1,881,250, with a grant period from 2017-2021.
VA Merit Award
“Targeting Platelet Endocytosis and Exocytosis to Control Thrombosis”
The amount of funding is $928,269 and the grant runs from 2017- 2021.
“Platelet Endocytosis to Innate Immunity”
The amount of funding is $2,044,892 and the grant runs from 2017-2021.
COBRE Pilot Award
Kentucky Lung Cancer Research Program Grant
“Acetylation of G3BP1 in Lung Cancer”
The amount of funding is $150,000 for the period 07/01/2017 to 06/30/2019. The major goal of the grant is to determine whether G3BP1 acetylation can promote lung cancer progression and whether targeting G3BP1 acetylation provides a novel therapeutic avenue for lung cancer.